Fig. 1
From: TREM2 risk variants and associated endophenotypes in alzheimer’s disease
Flowchart of population from the Amsterdam Dementia Cohort. Patients were included from the Amsterdam Dementia Cohort. TREM2 carriership was determined by whole exome sequencing (WES), SNP array, and targeted TaqMan assay (including TREM2 variants R47H and R62H); and TREM2 non-carriership was determined by WES. Patients were included with an amyloid confirmed diagnosis of mild cognitive impairment (MCI) or dementia based on Alzheimer’s disease. Abbreviations: A105V = p.Ala105Val; AD = Alzheimer’s disease; ADAD = Autosomal dominant Alzheimer’s disease; C51Y = p.Cys51Tyr; CSF = Cerebrospinal Fluid; D87N = p.Asp87Asn; G58A = p.Gly58Ala; MRI = Magnetic Resonance Imaging; SNP = Single-Nucleotide Polymorphism; Q33X = p.Gln33Ter; S31F = p.Ser31Phe; R47G = p.Arg47Gly; R47H = p.Arg47His; R62H = p.Arg62His; T96K = p.Thr96Lys; TREM2 = Triggering Receptor Expressed on Myeloid Cells 2; WES = Whole Exome Sequencing